KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) FCF Margin (2016 - 2025)

Rigel Pharmaceuticals has reported FCF Margin over the past 15 years, most recently at 31.51% for Q4 2025.

  • Quarterly results put FCF Margin at 31.51% for Q4 2025, up 637.0% from a year ago — trailing twelve months through Dec 2025 was 25.71% (up 817.0% YoY), and the annual figure for FY2025 was 25.71%, up 817.0%.
  • FCF Margin for Q4 2025 was 31.51% at Rigel Pharmaceuticals, down from 34.6% in the prior quarter.
  • Over the last five years, FCF Margin for RIGL hit a ceiling of 208.67% in Q2 2021 and a floor of 154.53% in Q1 2022.
  • Median FCF Margin over the past 5 years was 10.23% (2023), compared with a mean of 6.6%.
  • Biggest five-year swings in FCF Margin: skyrocketed 29602bps in 2021 and later tumbled -25185bps in 2022.
  • Rigel Pharmaceuticals' FCF Margin stood at 93.41% in 2021, then surged by 54bps to 42.87% in 2022, then surged by 59bps to 17.43% in 2023, then soared by 244bps to 25.14% in 2024, then increased by 25bps to 31.51% in 2025.
  • The last three reported values for FCF Margin were 31.51% (Q4 2025), 34.6% (Q3 2025), and 30.03% (Q2 2025) per Business Quant data.